Target Price | €43.94 |
Price | €39.46 |
Potential | 11.36% |
Number of Estimates | 18 |
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €43.94. This is 11.36% higher than the current stock price. The highest price target is €50.00 26.73% , the lowest is €39.53 0.18% . | |
A rating was issued by 22 analysts: 12 Analysts recommend Qiagen to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 11.36% . Most analysts recommend the Qiagen stock at Purchase. |
18 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 4.77% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 6.38% , the lowest is €1.8b 1.83% .
This results in the following potential growth metrics:
2024 | €1.7b | 0.66% |
---|---|---|
2025 | €1.8b | 4.77% |
2026 | €1.9b | 6.00% |
2027 | €2.1b | 6.66% |
2028 | €2.2b | 7.74% |
2029 | €2.4b | 7.56% |
17 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €679m . This is 52.73% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €754m 69.54% , the lowest is €620m 39.49% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €445m | 10.64% |
---|---|---|
2025 | €679m | 52.73% |
2026 | €732m | 7.82% |
2027 | €793m | 8.36% |
2028 | €861m | 8.47% |
2029 | €925m | 7.47% |
2024 | 25.51% | 9.92% |
---|---|---|
2025 | 37.18% | 45.77% |
2026 | 37.82% | 1.72% |
2027 | 38.42% | 1.59% |
2028 | 38.68% | 0.68% |
2029 | 38.64% | 0.10% |
11 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €391m . This is 430.42% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €448m 508.62% , the lowest is €333m 352.69% .
This results in the following potential growth metrics and future Net Margins:
2024 | €73.7m | 75.51% |
---|---|---|
2025 | €391m | 430.42% |
2026 | €433m | 10.95% |
2027 | €484m | 11.77% |
2028 | €534m | 10.27% |
2024 | 4.23% | 75.67% |
---|---|---|
2025 | 21.39% | 406.23% |
2026 | 22.39% | 4.68% |
2027 | 23.46% | 4.78% |
2028 | 24.01% | 2.34% |
11 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €1.81 . This is 465.63% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.07 546.88% , the lowest is €1.54 381.25% .
This results in the following potential growth metrics and future valuations:
2024 | €0.34 | 74.81% |
---|---|---|
2025 | €1.81 | 432.35% |
2026 | €2.01 | 11.05% |
2027 | €2.24 | 11.44% |
2028 | €2.47 | 10.27% |
Current | 124.22 | 307.40% |
---|---|---|
2025 | 21.99 | 82.30% |
2026 | 19.82 | 9.87% |
2027 | 17.73 | 10.54% |
2028 | 16.08 | 9.31% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.83 and an P/S ratio of 4.72 .
This results in the following potential growth metrics and future valuations:
Current | 5.06 | 8.99% |
---|---|---|
2025 | 4.83 | 4.54% |
2026 | 4.56 | 5.66% |
2027 | 4.27 | 6.25% |
2028 | 3.97 | 7.19% |
2029 | 3.69 | 7.03% |
Current | 4.94 | 5.76% |
---|---|---|
2025 | 4.72 | 4.56% |
2026 | 4.45 | 5.66% |
2027 | 4.17 | 6.25% |
2028 | 3.87 | 7.19% |
2029 | 3.60 | 7.03% |
Analyst | Rating | Action | Date |
---|---|---|---|
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Feb 07 2025 |
Morgan Stanley |
Overweight
➜
Equal-Weight
|
Downgrade | Jan 06 2025 |
HSBC |
Buy
➜
Hold
|
Downgrade | Oct 17 2024 |
Analyst Rating | Date |
---|---|
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Feb 07 2025 |
Downgrade
Morgan Stanley:
Overweight
➜
Equal-Weight
|
Jan 06 2025 |
Downgrade
HSBC:
Buy
➜
Hold
|
Oct 17 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.